The company is now at a crossroads of sorts. Gilead has a new CEO and possibly could have a different direction. It makes sense that current shareholders would rethink whether they should hold on to the stock and that other investors would carefully scrutinize the biotech's prospects.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,